Advances in Vaccines, Checkpoint Blockade, and Chimeric Antigen Receptor-Based Cancer Immunotherapeutics

被引：0

作者：

Agarwal, Disha ^{[1
]}

Sharma, Gaurav ^{[1
]}

Khadwal, Alka ^{[2
]}

Toor, Devinder ^{[3
]}

Malhotra, Pankaj ^{[2
]}

机构：

[1] Postgrad Inst Med Educ & Res, Dept Translat & Regenerat Med, 5th Floor Res Block B Sect 12, Chandigarh 160012, India

[2] Postgrad Inst Med Educ & Res, Dept Clin Hematol & Med Oncol, Chandigarh, India

[3] Amity Univ Uttar Pradesh, Amity Inst Virol & Immunol, Noida, India

来源：

CRITICAL REVIEWS IN IMMUNOLOGY | 2024年 / 45卷 / 01期

关键词：

vaccines; cancer; immunotherapy; CTLA-4; PD-1; CAR-T cells; CAR-NK cells; immune surveillance; immune exhaustion; MESSENGER-RNA VACCINES; NATURAL-KILLER-CELLS; T-CELLS; DENDRITIC CELLS; NK-92; CELLS; CD28; GENERATION; RESISTANCE; THERAPY; PD-1;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Increase in cancer cases and research driven by understanding its causes, facilitated development of novel targeted immunotherapeutic strategies to overcome nonspecific cytotoxicity associated with conventional chemotherapy and radiotherapy. These target specific immunotherapeutic regimens have been evaluated for their efficacy, including: (1) vaccines harnessing tumor specific/associated antigens, (2) checkpoint blockade therapy using monoclonal antibodies against PD1, CTLA-4 and others, and (3) adoptive cell transfer approaches viz. chimeric antigen receptor (CAR)-cellbased therapies. Here, we review recent advancements on these target specific translational immunotherapeutic strategies against cancer/s and concerned limitations.

引用

页码：65 / 80

页数：16

共 50 条

[31] Perspective: cancer vaccines in the era of immune checkpoint blockade
Cebon, Jonathan
MAMMALIAN GENOME, 2018, 29 (11-12) : 703 - 713
[32] Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
Petty, Amy J.
Heyman, Benjamin
Yang, Yiping
CANCERS, 2020, 12 (04)
[33] You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Pfefferle, Aline
Huntington, Nicholas D.
CANCERS, 2020, 12 (03)
[34] Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
Marvin-Peek, Jennifer
Savani, Bipin N.
Olalekan, Oluwole O.
Dholaria, Bhagirathbhai
CANCERS, 2022, 14 (03)
[35] Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines
A Q Butt
K H G Mills
Oncogene, 2014, 33 : 4623 - 4631
[36] B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
Zhang, Zheng
Xu, Qian
Huang, Liang
FRONTIERS IN IMMUNOLOGY, 2023, 14
[37] Chimeric antigen receptor T cell: A cancer immunotherapy
Singh, Surjit
Khasbage, Sameer
Kaur, Rimple Jeet
Sidhu, Jaspreet Kaur
Bhandari, Bharti
INDIAN JOURNAL OF PHARMACOLOGY, 2022, 54 (03) : 226 - 233
[38] Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
Shang, Yufeng
Zhou, Fuling
FRONTIERS IN ONCOLOGY, 2019, 9
[39] Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer
Moreno, Carlos
Haynie, Christopher
Cheever, Abigail
Weber, K. Scott
BIOMEDICINES, 2022, 10 (07)
[40] Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer
Rafei, Hind
Rezvani, Katayoun
BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (02) : 443 - 446

← 1 2 3 4 5 →